drugset / Trial / NCT07491263
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell infusion in subjects with CD19-positive R/R B-ALL.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2028-04-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QH103 Cell Injection | Cell therapy | 1e+08 cells | — |
| Subject | QH103 Cell Injection | Cell therapy | 3e+08 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Fludarabine | Small molecule | 40 mg/m2 | — |